接受利妥昔单抗治疗患者慢性鼻窦炎发病率研究
这项多中心回顾性队列研究纳入2019年1月至2025年1月期间处方利妥昔单抗的17851例患者,排除既往慢性鼻窦炎(CRS)者,发现1105例(6.2%)发生CRS,年发病率为1.03%(每10万人年1032例)。大多数CRS诊断发生在停药后(62.7%),停药至诊断的中位延迟为17.0个月。
要点
- 利妥昔单抗使用者CRS年发病率为1.03%,高于既往报道的普通人群水平。
- 62.7%的CRS诊断发生在利妥昔单抗停药后,中位延迟17.0个月。
- CRS评估时应详细回顾利妥昔单抗等用药史。
核心结论
- 利妥昔单抗治疗后CRS年发病率为1.03%,提示该人群风险可能增加。
研究设计与样本
- 多中心回顾性队列研究,纳入2019年1月至2025年1月处方利妥昔单抗的17851例患者,排除既往CRS者。
主要发现
- 17851例患者中1105例(6.2%)发生CRS,年发病率1.03%(每10万人年1032例)。
- CRS患者利妥昔单抗治疗中位时长5.9个月(IQR 0.5-42.6)。
- 62.7%(n=693)的CRS发生在停药后,37.3%(n=412)发生在治疗期间。
- 停药至CRS诊断的中位延迟为17.0个月(IQR 4.3-41.7)。
临床怎么用
- 对CRS患者进行病情评估时,应详细询问利妥昔单抗等免疫抑制药物使用史。
- 利妥昔单抗停药后仍需长期关注CRS相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rituximab causes B-cell depletion and hypogammaglobulinemia, increasing risk for infections. This study aims to determine the incidence of chronic rhinosinusitis (CRS) in patients following rituximab therapy. STUDY DESIGN: Retrospective cohort study using chart review of patients prescribed rituximab between January 2019 and January 2025. SETTING: Multisite study across Mayo Clinic Enterprise locations in Arizona, Florida, Minnesota, and Wisconsin. METHODS: Patients with documented rituximab use were included; those with pre-existing CRS were excluded. Demographic and clinical data-including timing and duration of rituximab therapy, CRS diagnosis, comorbidities (asthma, allergic rhinitis, GERD), and need for sinus surgery-were collected. Descriptive statistics summarized patient characteristics. Group comparisons were performed using t-tests, Mann-Whitney U, and chi-square tests. Analyses were conducted using SPSS v28. RESULTS: Among 17,851 patients prescribed rituximab (median age 64.0 years, M:F ratio 1.1:1), 1105 (6.2%) developed CRS, with an annual incidence of 1.03% (1032 cases per 100,000 person-years). The median duration of rituximab therapy for those diagnosed with CRS was 5.9 months (IQR, 0.5-42.6). Most CRS cases occurred after rituximab discontinuation (62.7%, n = 693) compared to during active treatment (37.3%, n = 412). The median delay between rituximab discontinuation and CRS diagnosis was 17.0 months (IQR, 4.3-41.7). CONCLUSIONS: This study demonstrates an annual incidence of 1.03% for CRS diagnoses following rituximab. While prior studies report varying CRS incidences in the general population (0.25%-0.73%), our findings suggest increased risk among rituximab users. Most CRS diagnoses occurred after rituximab discontinuation, emphasizing the need for a comprehensive medication history review during CRS evaluation.
引用
- Walker K, Valencia-Sanchez BA, Wilson P, et al. Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab. Otolaryngol Head Neck Surg. 2026. PMID: 42605935. doi:10.1002/ohn.70390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。